.Johnson & Johnson’s deprioritization of its own transmittable disease pipeline has asserted one more victim in the form of its own dengue virus vaccine mosnodenvir.Mosnodenvir is actually designed to block out communications between two dengue infection proteins. The vaccine made it through J&J’s selection in 2014 to combine its contagious ailment as well as vaccination functions, which found the likes of a late-stage breathing syncytial infection plan dropped coming from the Major Pharma’s pipe and an E. coli vaccination sold off to Sanofi.Mosnodenvir has possessed a rough time in the medical clinic, along with J&J terminating one litigation because of the impact of COVID-19 on application and stopping briefly recruitment in an additional study in 2022.
Yet the devotion to mosnodenvir showed up to settle in October 2023, when the vaccine was actually shown to cause a dose-dependent antiviral result on the detectability and also start of dengue infection serotype 3 in a phase 2 trial. That records decline doesn’t seem to have sufficed to spare mosnodenvir for long, along with the Big Pharma introducing this morning that it is actually discontinuing a follow-up phase 2 industry research. The selection is actually connected to a “critical reprioritization of the firm’s infectious health conditions R&D collection,” added J&J, which pressured that no safety and security issues had been actually recognized.” Johnson & Johnson are going to remain to support the fight against dengue by sharing research results with the health care area down the road,” the pharma mentioned in the release.J&J had actually been actually investing in dengue for over a decade, featuring releasing a Gps Facility for Global Health Discovery at the Duke-NUS Medical College in Singapore in 2022.
The facility has actually been actually focused on accelerating early-stage exploration investigation to “resolve the growing problem of flaviviruses” like dengue and also Zika.